IN8bio Quote - INAB

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Current Price

0.8322

Bid

0.7921

Ask

1.36

Volume

343,548

0.78 Day's Range 0.8991

0.65 52 Week Range 2.48

Market Cap

36.623M

Previous Close

0.8993

Open

0.885

Last Trade

1000

0.8322

(formt)

Last Trade Time

Financial Volume

US$ 289,716

VWAP

0.843307

Average Volume (3m)

576,382

Shares Outstanding

44,123,949

Dividend Yield

PE Ratio

-1.22

Earnings Per Share (EPS)

-0.68

Revenue

Net Profit

-30.01M

IN8bio Inc is a clinical-stage biotechnology company. It is focused on developing innovative therapies for the treatment of cancers, including solid tumors, by employing allogeneic, autologous and genetically modified gamma-delta T cells. IN8bio Inc is a clinical-stage biotechnology company. It is focused on developing innovative therapies for the treatment of cancers, including solid tumors, by employing allogeneic, autologous and genetically modified gamma-delta T cells.

Sector

Biological Pds,ex Diagnstics

Industry

Biological Pds,ex Diagnstics

Website

www.in8bio.com

Headquarters

Wilmington, Delaware, USA

Founded

1970

IN8bio Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker INAB. The last closing price for IN8bio was US$0.90. Over the last year, IN8bio shares have traded in a share price range of US$ 0.65 to US$ 2.48.

IN8bio currently has 44,123,949 shares outstanding. The market capitalization of IN8bio is US$36.62 million. IN8bio has a price to earnings ratio (PE ratio) of -1.22.

IN8bio to Present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference

NEW YORK, June 24, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today announced...

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

IN8bio Presents Positive Data Demonstrating Durable 1-year Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100

100% of treated leukemia patients (n=10/10) achieved durable complete remission (CR) at 1-year, including high-risk and relapsed acute myeloid leukemia (AML) patients who had previously failed...

Form 8-K - Current report

IN8bio Presents Progression-Free Survival Update from Phase 1 Study of INB-200 at 2024 American Society of Clinical Oncology Annual Meeting

92% of evaluable patients treated with INB-200 for glioblastoma exceeded a median progression-free survival (PFS) of seven months achieved with the standard-of-care regimen (Stupp regimen...

IN8bio to Present at International Society for Cell & Gene Therapy (ISCT) 2024

NEW YORK, May 24, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB) a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced multiple...

Period †	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-0.0698	-7.73835920177	0.902	0.9489	0.78	343914	0.88817407	CS
4	-0.2278	-21.4905660377	1.06	1.74	0.78	942457	1.21623469	CS
12	-0.2698	-24.4827586207	1.102	1.74	0.78	576382	1.15579556	CS
26	-0.5378	-39.2554744526	1.37	1.93	0.78	358271	1.18307581	CS
52	-0.8678	-51.0470588235	1.7	2.48	0.65	365244	1.33440579	CS
156	-9.1678	-91.678	10	10.319	0.65	590859	2.47167526	CS
260	-9.1678	-91.678	10	10.319	0.65	590859	2.47167526	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
DNDelta 9 Cannabis Inc	$ 0.015 (50.00%)	1.1M
BRMIBoat Rocker Media Inc	$ 1.02 (29.11%)	1.84M
TSATTelesat Corporation	$ 12.50 (17.26%)	3.24k
QECQuesterre Energy Corporation	$ 0.25 (16.28%)	24.6k
GEOGeodrill Limited	$ 2.30 (15.58%)	47.28k
NCPNickel Creek Platinum Corp	$ 0.01 (-33.33%)	1.07k
LPENLoop Energy Inc	$ 0.025 (-28.57%)	73.62k
ASNDAscendant Resources Inc	$ 0.035 (-22.22%)	1,000
FLNTFlint Corporation	$ 0.025 (-16.67%)	16.5k
BNGBengal Energy Ltd	$ 0.03 (-14.29%)	85k
TRPTC Energy Corporation	$ 51.87 (-1.76%)	34.35M
BNSBank of Nova Scotia	$ 62.58 (0.29%)	18.9M
POWPower Corp of Canada	$ 38.02 (-1.66%)	13.19M
TDToronto Dominion Bank	$ 75.20 (0.09%)	9.87M
MFCManulife Financial Corporation	$ 36.44 (0.41%)	6.48M